Surrozen, Inc./DE
Surrozen is a biotechnology company in South San Francisco, California, that discovers and develops product candidates designed to selectively modulate the Wnt pathway. Its current focus is ophthalmology, including retinal and corneal diseases. The company uses its SWAP antibody engineering technology to develop antibody-based Wnt mimetics intended to activate signaling in targeted tissue and support tissue repair. Surrozen is developing SZN-8141, which combines Fzd4 agonism and VEGF antagonism for diabetic macular edema and wet age-related macular degeneration, and SZN-8143, which also targets IL-6 for those conditions and uveitic macular edema. Its research programs address other retinal and corneal indications. Under a collaboration and license agreement, Boehringer Ingelheim researches, develops and commercializes Fzd4 bi-specific antibodies designed using SWAP, including SZN-413. Surrozen also earns milestone payments under that agreement.
No enriched coverage for $SRZN in the last 7 days.
No SEC Form 4 filings for $SRZN in the last 30 days.
See all $SRZN insider activity →Surrozen, Inc./DE (SRZN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million Proceeds strengthen balance sheet and provide expected cash runway into 2029 to advance SZN-8141 and SZN-8143 SOUTH SAN FRANCISCO, Calif., October 20, 2026 — Surrozen, Inc.
Surrozen (SRZN) raised about $95M in its final private placement tranche, extending its cash runway into 2029. The funds will support clinical trials for SZN-8141 and SZN-8143, targeting retinal diseases. The company issued shares and warrants as part of the financing.
Guggenheim Securities named Surrozen, Inc. its top biotech pick, with a Buy rating and $42 price target. The firm highlights the company's retinal vascular disease treatment, SZN-8141, and its potential in the Phase Ib/IIa DUET study. Guggenheim sees Surrozen as undervalued at a $730M market cap, with key catalysts expected by 2027.
Recent SRZN coverage spans financial news, earnings and regulation.
The sizable capital raise provides runway for clinical programs, likely supporting a positive re‑rating and short‑term price appreciation.
The capital raise strengthens the balance sheet and funds pipeline milestones, likely supporting the stock.
Street endorsement centers on SZN-8141’s Wnt plus anti-VEGF approach and near-term clinical execution milestones (DUET start and later topline).
Positive regulatory milestone for a micro‑cap biotech.
The IND clearance removes a regulatory hurdle, allowing clinical dosing and unlocking capital, which could lift the stock on trial progress expectations.
AlphAI scores every news story that mentions SRZN with an AI model for sentiment and relevance, and aggregates insider trades from Surrozen, Inc./DE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Surrozen, Inc./DE (SRZN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million Proceeds strengthen balance sheet and provide expected cash runway into 2029 to advance SZN-8141 and SZN-8143 SOUTH SAN FRANCISCO, Calif., October 20, 2026 — Surrozen, Inc.
2 min readSurrozen (SRZN) raised about $95M in its final private placement tranche, extending its cash runway into 2029. The funds will support clinical trials for SZN-8141 and SZN-8143, targeting retinal diseases. The company issued shares and warrants as part of the financing.
2 min readGuggenheim Securities named Surrozen, Inc. its top biotech pick, with a Buy rating and $42 price target. The firm highlights the company's retinal vascular disease treatment, SZN-8141, and its potential in the Phase Ib/IIa DUET study. Guggenheim sees Surrozen as undervalued at a $730M market cap, with key catalysts expected by 2027.
4 min readSurrozen, Inc./DE (SRZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development. The IND went into effect
2 min readSurrozen (SRZN) received FDA clearance for its IND application for SZN-8141, a treatment for diabetic macular edema. The company plans to begin dosing patients in Q4 2026. This milestone triggers a $95.1M second closing of a private placement. The funds will support the development of SZN-8141 and SZN-8143, as well as broader operating activities.
2 min readGuggenheim analyst Yatin Suneja named Surrozen Inc (SRZN) as the top biotechnology stock pick, citing progress in eye disease treatments. The company submitted an Investigational New Drug application for SZN-8141, triggering $98.4 million in funding. Guggenheim expects smooth IND clearance and clinical study initiations by late 2026. The analyst also noted upcoming Merck study results that could impact the sector.
2 min readInvesting.com reports Guggenheim named Surrozen Inc. (SRZN) its top biotech stock pick, reiterating a Buy rating. The focus is the Phase IIb/III BRUNELLO readout, with primary completion expected in September and full data potentially in October. Guggenheim cites potential upside of 2 to 3 times current levels and highlights SRZN-8141/8143 and upcoming DUET timing.
3 min readSurrozen, Inc./DE (SRZN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initia
5 min readInvesting.com reported Friday’s notable U.S. insider transactions. ClearSign (CLIR) director bought 500,000 shares for $1.77M at $3.54. Five Star Bancorp (FSBC) director bought 96,591 shares for $4.25M at $44. Rhinebeck Bancorp (RBKB) directors and CEO bought shares totaling about $596k. Levi (LEVI) CFO sold 98,144 shares for $2.38M. State Street (STT) sold 14,553 shares for $2.68M; Travelers (TRV) sold 6,000 for $2.2M; Domino’s (DPZ) sold about $4.0M.
4 min readTCG Crossover GP II, LLC sold 325,000 indirectly-held shares of Surrozen, Inc./DE (SRZN) at $21.25 ($6.91M total) across 2 trades on 2026-07-22.
2 min read